Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 24.8.2020 | EN | Official Journal of the European Union | C 279/50 |

---

Action brought on 26 June 2020 — Allergan Holdings France v EUIPO — Dermavita Company (JUVEDERM)

(Case T-397/20)

(2020/C 279/63)

Language of the case: English

Parties

Applicant: Allergan Holdings France SAS (Courbevoie, France) (represented by: J. Day, Solicitor and T. de Haan, lawyer)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Dermavita Company SARL (Beirut, Lebanon)

Details of the proceedings before EUIPO

Proprietor of the trade mark at issue: Applicant before the General Court

Trade mark at issue: European Union word mark JUVEDERM — European Union trade mark No 2 196 822

Procedure before EUIPO: Cancellation proceedings

Contested decision: Decision of the Fourth Board of Appeal of EUIPO of 14 April 2020 in Case R 877/2019-4

Form of order sought

The applicant claims that the Court should:

|  |  |
| --- | --- |
| — | annul points 3 and 4 of the operative part of the decision insofar as it dismissed the applicant appeal against the revocation of its EU trade mark registration No 2 196 822 JUVEDERM for ‘dermal implants’, and ordered the applicant to bear its own costs; |

|  |  |
| --- | --- |
| — | order EUIPO and Dermavita Company Ltd to bear their own costs and pay those of the applicant, including those incurred by the applicant before the Fourth Board of Appeal. |

Pleas in law

|  |  |
| --- | --- |
| — | Infringement of Article 58(1)(a) of Regulation (EU) 2017/1001 of the European Parliament and of the Council; |

|  |  |
| --- | --- |
| — | Infringement of Article 64(5) of Regulation (EU) 2017/1001 of the European Parliament and of the Council. |

---

[Top](#document1)